Genome Medical uses specially formatted clinical-quality data to improve genomics

Genome Medical makes genetic care accessible and usable for patients by providing access to genetic services seven days a week. By collaborating with healthcare systems, molecular testing laboratories and life sciences organizations, Genome Medical is expanding the practice and impact of genomic medicine to improve patient care.

An example of how it does this is by supporting biopharmaceutical organizations in accelerating the design, development and time to launch of life-enhancing therapies.

While it has already worked with biopharmaceutical companies in various ways, it knew there were opportunities to expand its reach and impact.

Clinical formatted data

To help leverage this opportunity, Genome Medical has partnered with a vendor called xCures, which processes medical data in various formats and converts it into a streamlined, clinical format that can be used by both patients and physicians.

“Working together with xCures gave us the opportunity to help our partners further accelerate clinical trials by identifying clinically qualified trial participants,” said Jill Davies, CEO of Genome Medical. “With xCures, we are able to expand on the patient data we already have – adding more robust clinical patient histories from the EHR, such as diagnoses, medications, previous treatments and more.”

Genome Medical provides genetic counseling to more than 6,000 patients every month. Through the collaboration with xCures, and with patient consent, medical records can be accessed within minutes through the exchange of health information and a secure search platform.

“After adding this additional insight into the patient’s clinical history, we apply AI algorithms that feed inclusion/exclusion criteria (I/E) to find eligible patients for specific clinical trials,” Davies explains. “By adding additional clinical data to each record through xCures, we have a robust and continuously growing patient population that we can identify and activate for clinical trials.

“And with our deep genetics and clinical expertise and strong patient-provider relationships, we are turning the tide on a traditionally slow, cumbersome trial enrollment process,” she added.

Large network of specialists

Genome Medical claims to have the largest national network of telehealth genetic specialists, who average ten years of clinical experience and cover a spectrum of clinical specialties including oncology, reproductive health, cardiology, pediatrics, rare diseases and proactive health.

“This positions us to help our partners and their patients navigate the often intimidating and confusing diagnostic journey to find a clinical trial or genetic therapy that helps them better manage their health conditions,” Davies said.

The organization’s use cases and outcomes span the spectrum from high-volume chronic conditions to low-incidence rare diseases. For example, Davies reported:

  • One clinical trial required participants for an extremely rare disease that affects one in 70,000 to 100,000 people. Genome Medical identified seven eligible patients.
  • A clinical trial for a common chronic disease required complex patient matching criteria, including a coded diagnosis, a specific prescription within the past twelve months without concurrent use of other excluded medications and treatments, the exclusion of several other conditions, and more . The organization identified 161 patients.
  • And a clinical oncology trial required patients with specific genetic markers plus the exclusion of previous treatments. The organization identified 33 patients.

“During our patient intake process for the provision of genetic counseling services, we may offer patients the opportunity to contact Genome Medical again if we become aware of a clinical trial relevant to their clinical condition,” Davies noted.

Complete review of clinical records

“So after matching the I/E criteria I mentioned, our team of genetics experts will conduct a full review of the clinical records for all qualified patients who meet the criteria,” she continued. “For those that do, we can contact them directly and provide them with clinical trial enrollment information if interested.”

The process of identifying, assessing, recontacting and connecting each of these cohorts was completed in less than two weeks.

“Leveraging the available clinical data and technology is critical to advancing successful clinical trials, but even AI must include the human element – ​​for quality of care and for patient engagement,” Davies advised her colleagues. “At Genome Medical, that human element is our clinical expertise and a trusted patient-provider relationship.”

Follow Bill’s HIT coverage on LinkedIn: Bill Siwicki
Email him:
Healthcare IT News is a HIMSS Media publication.